HealthAIdir logoHealthAIdir

EarliPoint Assessment

Conditional
Official website link included
Last reviewed 2026/06/17
Published 2026/06/17

FDA-listed AI-enabled medical device candidate for healthcare AI buyers.

EarliPoint Assessment is a Phase 7 candidate from the FDA AI-enabled medical devices list. Maker: Earlitec Diagnostics. Panel: Psychiatry. HealthAIdir lists it as a conditional seed profile pending deeper vendor evidence review.

Visit Website

This page may include affiliate links or demo-request routing. Commercial relationships do not affect HealthAIdir scores, verdicts, rankings, or recommendations.

No preview image
Visit Website

Introduction

EarliPoint Assessment is included in the Phase 7 formal seed expansion as a conditional healthcare AI directory profile. The current entry is anchored on FDA AI-enabled medical device list and FDA database entry, with procurement details still requiring primary-source review.

HealthAIdir treats this page as a shortlist starting point rather than a final recommendation. Buyers should confirm product scope, deployment model, pricing, privacy terms, security controls, and compliance claims before using it in a live healthcare workflow.

Best fit

  • Clinical AI teams tracking newly listed FDA AI-enabled medical devices
  • Radiology, cardiology, dental, or specialty leaders building review shortlists
  • Buyers who can validate FDA entry, product availability, and local deployment requirements

Not a fit

  • Teams that need a complete vendor procurement file without further source review
  • Buyers treating FDA list inclusion as a full clinical or commercial endorsement

Pros

  • Adds coverage for a relevant healthcare AI or health data workflow area
  • Has an official FDA list or database source to anchor initial review
  • Useful for shortlist discovery before deeper procurement diligence

Cons

  • Pricing was not fully verified during Phase 7 promotion
  • Privacy, security, and compliance pages still need detailed source review
  • Implementation fit depends on local workflow, integrations, and contract terms

Pricing

Pricing summary

No public pricing source was found during the 2026-06-17 Phase 7 evidence pass; pricing remains unknown and should be confirmed with the vendor or an official pricing page.

Implementation notes

Promote only after FDA database entry plus vendor product, pricing, privacy, security, and compliance pages are reviewed. Confirm workflow owner, integration path, clinical or administrative review steps, support model, and rollout controls before procurement.

Compliance review

HIPAA

Not reviewed

BAA

Not reviewed

Official evidence sources captured for review: regulatory/context https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices; regulatory/context https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K253442. Treat HIPAA, BAA, SOC 2, HITRUST, FDA, MDR, and PHI handling claims as unconfirmed until the linked sources are manually reviewed.

Data handling

Vendor-side PHI, retention, access-control, subprocessors, and model-training evidence was not found during this pass.

Integrations

Clinical workflow
Imaging or specialty system
Vendor deployment environment

Questions to ask before a demo

Use these questions to turn this profile into a buyer-side evidence checklist. HealthAIdir does not verify production readiness, clinical safety, compliance approval, coding accuracy, billing accuracy, or legal suitability.

  1. 1

    Which healthcare workflow does EarliPoint Assessment support best?

    Ask the vendor to map supported users, handoffs, review steps, and failure modes to your clinical, revenue cycle, or operations workflow.

  2. 2

    What evidence should be reviewed before a pilot?

    Request source documentation, validation notes, customer scope, update history, and implementation assumptions rather than relying on marketing claims.

  3. 3

    How should the compliance and data handling claims be verified?

    Confirm PHI flow, BAA availability, privacy terms, security controls, audit logs, subprocessors, and whether claims are contractual or only descriptive.

  4. 4

    What integration and implementation work is required?

    Clarify EHR, billing, identity, data export, monitoring, support ownership, training, timeline, and rollback requirements.

  5. 5

    What pricing, contract, and pilot success criteria should be confirmed?

    Review pricing unit, minimum commitments, renewal terms, cancellation, support scope, measurable pilot outcomes, and buyer-side responsibilities.

Related research

Continue researching EarliPoint Assessment.

Use explicit comparisons and alternative tool profiles to keep shortlist research connected to source evidence.

Category path

Diagnostics

AI tools for medical imaging, diagnosis support, triage, and diagnostic workflows.

Open path
Tag path

2026 FDA AI Device

Tag for 2026 fda ai device content expansion.

Open path
Tag path

Autism Assessment AI

Tag for autism assessment ai content expansion.

Open path
Free checklist

Run the healthcare AI procurement checklist

Convert profile findings into a vendor due diligence checklist.

Open path
Solution guide

Browse workflow solution guides

Map this tool to healthcare AI workflows before planning a pilot.

Open path
Glossary

Clarify healthcare AI terminology

Review PHI, BAA, compliance, validation, and procurement terms.

Open path

FAQs

Is EarliPoint Assessment ready to buy based on this profile alone?
No. This is a conditional seed profile intended for discovery. Pricing, security, privacy, compliance, and implementation evidence should be verified directly from primary vendor or regulatory sources.
Why is EarliPoint Assessment included in HealthAIdir?
It appears in the FDA AI-enabled medical devices source set used for Phase 7 expansion.
Back

Information

Compliance snapshot

  • HIPAANot reviewed
  • BAANot reviewed
  • Editorial disclosure

    HealthAIdir promoted this Phase 7 seed profile from public source research. No vendor paid for placement. Buyers should verify all claims directly with Earlitec Diagnostics.

  • Editorial boundary

    Featured or sponsor placement does not affect HealthAIdir scores, verdicts, comparisons, or editorial recommendations.

Evidence and sources

Evidence links summarize public source material for traceability. They are not medical, billing, security, HIPAA, BAA, or compliance approval.

FDA list row captured with submission K253442. FDA list inclusion is an authorization signal, not an editorial endorsement. Promotion note: Phase 7 formal seed entry is based on public source anchors and remains conditional until product, pricing, privacy, security, compliance, and implementation details are rechecked. Phase 7 evidence pass 2026-06-17T00:00:00.000Z: homepage: not found product: not found privacy: not found security: not found pricing: not found compliance: not found regulatory/context: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-ena...

Show remaining evidence note

bled-medical-devices, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K253442 No pricing, HIPAA, BAA, SOC 2, HITRUST, or clinical-safety claim is asserted unless an official source URL is listed above and manually reviewed.

Updated 77 days ago from a recorded review event (2026/06/17).

Categories

Tags

More Healthcare AI Tools

AI Platform 2.2

Diagnostics

AI Platform 2.2 is a Phase 7 candidate from the FDA AI-enabled medical devices list. Maker: Exo Imaging. Panel: Cardiovascular. HealthAIdir lists it as a conditional seed profile pending deeper vendor evidence review.

Conditional
Last reviewed 2026/06/17
Compliance notes
Read review
2026 FDA AI DeviceCardiac Ultrasound AIMedical Imaging AI

AI-Rad Companion Brain MR

Diagnostics

AI-Rad Companion Brain MR is a Phase 7 candidate from the FDA AI-enabled medical devices list. Maker: Siemens Healthcare. Panel: Radiology. HealthAIdir lists it as a conditional seed profile pending deeper vendor evidence review.

Conditional
Last reviewed 2026/06/17
Compliance notes
Read review
2026 FDA AI DeviceMRI Reconstruction AIRadiology Worklist AI

AI4CMR v2.0

Diagnostics

AI4CMR v2.0 is a Phase 7 candidate from the FDA AI-enabled medical devices list. Maker: Ai4medimaging Medical Solutions. Panel: Cardiovascular. HealthAIdir lists it as a conditional seed profile pending deeper vendor evidence review.

Conditional
Last reviewed 2026/06/17
Compliance notes
Read review
2026 FDA AI DeviceCardiac Ultrasound AIMRI Reconstruction AI

Newsletter

Get Healthcare AI Briefings

Monthly procurement notes on clinical AI categories, validation, compliance, and vendor changes.